HighTower Advisors’s DiaMedica Therapeutics DMAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$141K Sell
17,000
-75
-0.4% -$524 ﹤0.01% 3631
2026
Q2
$120K Buy
17,075
+6,076
+55% +$37.3K ﹤0.01% 3634
2026
Q1
$74.5K Buy
+10,999
New +$87.2K ﹤0.01% 3668

Other funds holding DMAC

HighTower Advisors's DMAC Position: Q3 2026 in Review

HighTower Advisors reduced its DiaMedica Therapeutics (DMAC) stake by 0.44% in Q3 2026, selling an estimated $524 and leaving 17,000 shares worth $141K. The position accounts for ﹤0.01% of the portfolio, ranked #3631.

HighTower Advisors first reported a position in DMAC in Q1 2026 and has held it in 3 quarters since. 73 funds tracked by Wall St. Rank hold DMAC as of Q3 2026.

  • HighTower Advisors held 17,000 shares of DiaMedica Therapeutics worth $141K as of Q3 2026.
  • HighTower Advisors sold 75 DiaMedica Therapeutics shares in Q3 2026, an estimated $524.
  • DiaMedica Therapeutics made up ﹤0.01% of HighTower Advisors's portfolio in Q3 2026, its #3631 holding.
  • HighTower Advisors first reported a position in DiaMedica Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 73 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q3 2026.

Based on HighTower Advisors's 13F filing for Q3 2026, filed 10 Nov 2026.